Work

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2013

Authors: Eudocia Quant Lee, David A. Reardon, David Schiff, Jan Drappatz, Alona Muzikansky, Samantha Hammond, Sean Aaron Grimm, Andrew David Norden, Rameen Beroukhim, Christine Sceppa McCluskey, Andrew S. Chi, Tracy Batchelor, Katrina H. Smith, Sarah C. Gaffey, Mary Gerard, Susan M. Snodgrass, Jeffrey J. Raizer, Patrick Y. Wen

Institutions: Dana-Farber Cancer Institute, University of Virginia Medical Center, University of Pittsburgh, Massachusetts General Hospital, University of Minnesota, Northwestern University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599570809

Cites:

Cited by: 28

Related to: 10